



**IJPPR**

INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH  
An official Publication of Human Journals

ISSN 2349-7203




Human Journals

**Review Article**

April 2020 Vol.:18, Issue:1


© All rights are reserved by Vipin Kumar et al.

## Antimicrobial Stewardship Programme (AMSP)



**IJPPR**  
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH  
An official Publication of Human Journals

ISSN 2349-7203



HUMAN

**Vipin Kumar<sup>1\*</sup>, Malvika<sup>2</sup>, Sachin Gupta<sup>3</sup>, Swadesh kumar<sup>4</sup>, Satish Kaul<sup>5</sup>, Vipin kumar sharma<sup>6</sup>, Ankita singh<sup>7</sup>**

*1 (Clinical pharmacologist) Narayana superspecilty Hospital Gurugram*

*2 (Microbiologist, Infection control officer) Narayana superspecilty Hospital Gurugram*

*3 (Critical care, H. O. D) Narayana superspecilty Hospital Gurugram*

*4(Deputy medical Superintendent & Head Emergency) Narayana superspecilty Hospital Gurugram*

*5(Internal Medicine, H.O.D) Narayana superspecilty Hospital Gurugram*

*6(Assitant professor) Gurukul kangri university Haridwar*

*7(Clinical Pharmacist) BLK Hospital New Delhi*

**Submission:** 20 March 2020  
**Accepted:** 28 March 2020  
**Published:** 30 April 2020

**Keywords:** Antimicrobial Stewardship Programme (AMSP), Core Element, Role of Individual, Diagnostic Stewardship

### ABSTRACT

Antimicrobial resistance is an increasing finding among hospitalized patients and lots of these multidrug-resistant organisms are rampantly present in hospital settings. Antimicrobial stewardship programme (AMSP) has become a critical responsibility for all antimicrobial prescribers and health care providers. Aim of this study is to optimize antimicrobial use among patients to scale back antibiotic resistance, improve patient outcome, safety and price effective therapy provide. This review describes the why, what, how, when, and where, of Antimicrobial stewardship.



HUMAN JOURNALS

[www.ijppr.humanjournals.com](http://www.ijppr.humanjournals.com)

## INTRODUCTION

Widespread use of antimicrobial agents has been among the foremost important public health intervention within the last century<sup>1</sup>. The effect of those agents, alongside improved sanitation and the broad application of vaccination (in those countries where these are available), has shown a considerable reduction in infectious mortality<sup>2</sup>.

Antimicrobial resistance is a growing problem and the major contributing factor to this disconcerting development is insufficient use of antimicrobials, both in health-care centers and outpatient settings<sup>3</sup>, in livestock<sup>4</sup>. The so-called One Health approach targets resistance development on all the before-mentioned levels. An enormous effort is being made so as to effectively minimize the worldwide health-care antimicrobial resistance threat<sup>5</sup>. Consistent with this approach is improving the usage of antimicrobials in health-care centers and outpatient settings, which successively helps reducing resistance development<sup>6</sup>. Antimicrobial Stewardship Programs (AMSPs) are being hailed as a solution to improve antimicrobial therapies and thus end in a far better patient outcome and safety. Different national and international guidelines are available for hospitals, long-term care facilities, and general practitioners<sup>7, 8</sup>. No clear consensus on the impact of various interventions. Clinical and financial has been formed. Some interventions might even be counterproductive<sup>9, 10</sup>.

## ANTIMICROBIAL STEWARDSHIP HISTORY

In 1940s by Fleming, who discovered the waning efficacy of penicillin thanks to its overuse, the concept of antibiotic stewardship isn't new<sup>11</sup>. The growing threat of antibiotic resistance had led infectious-disease professional organizations to supply support and guidelines to combat the growing threat<sup>12</sup>. In 2009, the CDC launched the primary educational effort to market improved use of antibiotics in acute-care hospitals, and in 2013, the agency highlighted the necessity to enhance antibiotic use together of 4 key strategies required to deal with the matter of antibiotic resistance within the U.S.<sup>13, 14</sup>.

According to accrediting agencies like the Joint Commission and Government-based organizations, including the Centers for Medicare & Medicaid Services (CMS) came to the fore, the necessity and importance of Antimicrobial Stewardship Programs (AMSPs) across a spread of clinical practice areas. In January 2017, efforts were made in calling for all hospitals to possess stewardship programs recommendations by the Joint Commission<sup>15</sup>. In

addition, CMS proposed a rule change that might require all hospitals within us to implement an ASP.16.

### THE EMERGENCE OF ANTIMICROBIAL STEWARDSHIP

The search term “(antimicrobial OR antibiotic) AND stewardship” results first appeared on PubMed in 1996 and reaching over 10 hits per annum in 2005, and 50 hits per annum in 2008., in 2011 100 hits per annum, the entire number of citations identified by this search term. Now over 2500, thanks to its exponential use within the last five years.

**Table No. 1: Descriptions of antimicrobial stewardship from the literature**

Types of Description of AMS	EXAMPLE FROM THE LITERATURE
Description of activities	Antimicrobial stewardship includes selection, dose and duration of treatment, also as control of antibiotic use <sup>9</sup> . Antimicrobial stewardship refers to the responsible use of antimicrobials by healthcare professionals and providers and more specifically define to selection of the foremost appropriate antibiotic, duration, dose, and route of administration for a given patient with a demonstrated or suspected infection <sup>36</sup> .
Description of goals	The primary goal of antimicrobial stewardship is to optimize safe and appropriate use of antibiotics to enhance clinical outcomes and minimize adverse effect of antibiotics .unintended consequences of antimicrobial use, including toxicity, the choice of pathogenic organisms, and therefore the emergence of resistance <sup>15</sup> .
As a programmer set of interventions	AMS refers to a coordinated design to enhance and measure the acceptable use of antimicrobial agents by promoting the choice of the optimal antimicrobial drug regimen including dosing, duration of therapy and route of administration <sup>16,37</sup> . Antimicrobial stewardship is defined as interventions to enhance the acceptable use of antimicrobials through promotion of optimal agent selection, dosing, duration, and route of administration <sup>38</sup> . Antimicrobial stewardship refers to a program or series of interventions to watch and direct antimicrobial use at a healthcare institution, thus providing a typical, evidence-based approach to judicious antimicrobial use <sup>1</sup> A program that supports selection of, dosing, routes of administration and duration of antimicrobial therapy <sup>39</sup>
As an approach	Antimicrobial stewardship refers to the multifaceted approach

“Antimicrobial stewardship” article was first published by John E. McGowan Jr and Dale N. Gerding within USA<sup>16</sup>. They wanted to spotlight that antimicrobials should be considered as a precious non-renewable resource. Consistent with McGowan and Gerding, the term was inspired by a Sunday homily about the gospel of the “good steward” and therefore the use of the term “being an honest steward” or “stewardship” as a part of contributing regularly to the support of the church. “Antimicrobial stewardship” was then included by these two American colleagues within the 1997 Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA) guidelines for the prevention of antimicrobial resistance in hospital<sup>17</sup>.

Taken up by two European colleagues in 1999, Ian Gould and Jos van der Meer, term then crossed the Atlantic<sup>18</sup>, following informal contacts among these colleagues. In 1998, Ian Gould and Jos van der Meer founded ESGAP (the European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial stewardship, which helped amplify the utilization of “antimicrobial stewardship” worldwide.

### **Antimicrobial stewardship matures**

“Antimicrobial stewardship” was mostly utilized in the tiny level of programmers within individual hospitals<sup>19</sup>. 1990s and 2000s during programmes developed and implemented in many countries, often led by pharmacists within the US, and in Europe by specialists in infectious diseases physician or clinical microbiology, alongside a pharmacist and infection control staff. These programmers not always called AMS programmes, the shortage of the same for “stewardship” in many languages. As examples, antimicrobial stewardship is typically translated into ‘(programme) bon usage des antibiotiques’ (= programme of excellent antibiotic use) in French, ‘Strategienzumrationalen Einsatz von Antiinfektiva’ (=strategy of rational use of anti-infectives) in German, and ‘rationeelantibioticabeleid/policy in dutuch.

### **STEWARDSHIP MEAN**

According to Web of Science, “stewardship” has mostly been utilized in the ethics, policy, economics, theology, and it had rarely been used until the 1990s. Consistent with the Merriam-Webster dictionary<sup>20</sup>, stewardship refers to: “1: the office of something; especially: the careful and responsible management of something entrusted to one's care”. During the center Ages stewardship first appeared in English, it functioned as employment description,

denoting the office of a steward, or manager of an outsized household. Its range of reference spread to the oversight of law courts, employee unions, college dining halls, Masonic lodges, and lots of other organizations over the centuries. In recent years, a positive meaning, “careful and responsible management”.

The most cited description of AMS in recent years is that suggests by IDSA in 2007, which described AMS in terms of its goals (Table 1)<sup>21</sup>. This in 2012 IDSA updated, writing that “AMS refers to coordinated interventions designed to enhance and measure the acceptable use of antimicrobial agents by promoting the choice of the optimal antimicrobial drug regimen including selection of dosing, duration of therapy and route of administration”<sup>22</sup>.

This concept AMS a selected purpose; however, by remaining focused on individual prescriptions overlooks the stewardship roles of non-prescribers, and it encounters another problem common with many other descriptions: the other terms said appropriate, rational or optimal don't explicitly consider the necessity to balance individual and societal needs, then background the inherent value judgment implied by “responsible”.

Table 1 show that the term AMS has previously been defined during a sort of ways, including expressions of its objectives, its approaches and methods and its broader purposes. The broad descriptions of AMS has expanded over time, mirroring its application in an increasing number and variety of contexts. By this happening the main target has diverted from technical descriptions (drug, dose, duration, etc.) to concepts of responsibility.

Table 1 shows that the term AMS has previously been illustrated during a sort of ways, including expressions of its objectives, its approaches and methods and its broader purposes. The broad of descriptions of AMS has expanded over time, mirroring its application in an increasing number and variety of contexts. By this happening the main target has diverted from technical descriptions (drug, dose, duration, etc.) to concepts of responsibility.

Why we need antimicrobial stewardship?

Nowadays in the field of antibiotics, new drug development are available to treat bacterial infection. Between 1935 and 2003 fourteen new class of antibiotics were introduced. U.S ICU (intensive care unit) report back to CDC, *Staphylococcus aureus* isolates were immune to methicillin in 2003<sup>23</sup>. The speed of invasive methicillin-resistant *S. aureus* infections in

health care settings was shown to be decreasing during a 2010 Centers for Disease Control and Prevention study<sup>24</sup>, isolates intermediately or overtly immune to vancomycin are getting less rare<sup>25</sup>. Most difficulty to manage has been the rise in gram-negative resistance<sup>26</sup>.

Some programs run the international SMART (Study for Monitoring Antimicrobial Resistance Trend)<sup>27</sup> and therefore the SENTRY Anti-microbial Surveillance Program have shown substantial increases within the rate of *Klebsiella* resistance to 3<sup>rd</sup> generation cephalosporins, extended-spectrum lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* and *Pseudomonas* immune to fluoroquinolones<sup>23, 28, 29</sup>.

In previous 30 years, antibiotic development has slowed considerably and our options for treating increasingly resistant infections are getting more and more limited. This review aims to explain the why, what, who, how, when, and where of antimicrobial stewardship.

Every year Tens of thousands of USA citizens die of infections thanks to antibiotic-resistant pathogens. Only 10 new antibiotics are approved in 1998 only 2 of which (linezolid and Daptomycin) even have new targets of action.

Antibiotic orders 50% are unnecessary in hospitals. All of this has led the Infectious Diseases Society of America's Bad Bugs, No Drugs task force to involve a worldwide commitment from stakeholders to support the event of 10 new drugs in novel classes by the year 2020. This so-called 10 × 20 initiative has been likened to John F. Kennedy's dream of walking on the moon.

### **Strategies/approaches to antibiotics stewardship**

- 1-Antimicrobial therapy Appropriateness
- 2-Observed antimicrobial prophylaxis for operative procedures.
- 3- Antibiotics policies and standard treatment guidelines developing and implementing.
- 4-Auditing and providing feedback and timely intervention in streamlining the antibiotics prescriptions.

### **Strategies**

- 1-Active strategy
- 2-Supplemental strategy
- 3-Other strategies
  - a-Information Technology
  - b-Role of microbiology laboratory

c-Monitoring of process and outcomes measurement

d-Comprehensive Multidisciplinary antimicrobial management program,

**Table No. 2: SUMMARY OF ANTIMICROBIAL STEWARDSHIP<sup>31</sup>**


Stagey	Procedure	Person	Advantage	Disadvantage
Education guidelines	Creation of guidelines for antimicrobial use Group or individual education of clinicians by educators	antimicrobial committee to create guidelines Educators (physicians, pharmacist)	May alter behavior patterns Avoids loss of prescriber autonomy	Passive education likely ineffective
Formulary/ restriction	Restrict dispensing of targeted antimicrobials to approved indication	antimicrobial committee to create guidelines approval personnel (physician, infectious diseases fellow, clinical pharmacist)	Most direct control over antimicrobial use Individual educational opportunities	Perceived loss of autonomy for prescribers Need for all-hours consultant availability
Review and feedback	Daily review of targeted antimicrobial for appropriateness contact prescriber with recommendation for alternative therapy	Antimicrobial committee to create guidelines Review person (clinical Pharmacologist)	Avoid loss of autonomy for prescribers individual educational opportunities	Compliance with recommendation's voluntary
Computer Assistance	Use of information technology to implement previous strategies Expert System provide patient specific recommendations at point of care	Antimicrobial committee to create rules for computer system. For approval (phycians, pharmacist) Computer program	Provide patient specific data where most likely to impact (point of care facilities )	Significant time and resources investment to implement sophisticated system
Antimicrobial cycling	Schedule rotation of antimicrobial used in hospital or unit (eg: ICU)	Antimicrobial committee to create CYLING protocol Personnel to oversee adherence (Physician, Pharmacist)	May reduce resistance by changing selective pressure	Difficult to ensure adherence to cycling protocol. Theoretical concerns about effectiveness

## ANTIBIOTICS STEWARDSHIP CORE ELEMENT

The CDC recognized the growing threat of antibiotic-resistant organisms and therefore the importance of employing antibiotic.

Antibiotics Stewardship defined by CDC because of commitment and action designed to optimize the treatment of infection<sup>33</sup>.

All healthcare aimed to improving antibiotic related patient safety and slowing the spread of antibiotics resistance.



**Figure No. 1: Core elements of AMS<sup>34</sup>**

## ROLE OF INDIVIDUAL IN ANTIMICROBIAL STEWARDSHIP PROGRAMS (AMSP)

The participation of specific clinicians has been suggested because the key to having successful ASP team<sup>34</sup>.

**1-Infectious Diseases Physicians (Director) = ID physician,** lead physician and supervise the general function of the AMSP, make recommendation of the AMSP team and contributes to the tutorial activities. ID Physician provide supportive effort to enhance antibiotics use within the hospitals via assessing, monitoring and communicating the changes by setting standard antibiotic's prescribing practice.

**2-CLINICAL PHARMACOLOGIST (CO-DIRECTOR) = ID Pharmacologists** provide suggestion to clinicians on preferred first line antimicrobials and review medication orders.



They may also flag orders for review by infectious diseases specialists, additionally to their usual role in assuring proper dosing and safety.

Clinical pharmacologist is involved in antimicrobial stewardship programs, clinical pharmacist specialists in infectious diseases share responsibility for variety of activities. These include development of guidelines for antimicrobial use, education of physicians and other health care professionals, review of hospital antimicrobial orders with feedback to providers, administration of restrictive strategies, pharmacokinetic consultation, and research Program outcomes<sup>36</sup>.

Properly trained clinical pharmacists acting together with their physician colleagues can make substantial impact on patient care during a sort of practice areas, including infectious diseases<sup>37, 38, 39</sup>.

Gross et al. implemented an antimicrobial stewardship team to work out stewardship program at their teaching hospital Pharmacists were required to receive approval by paging a fanatical beeper<sup>40</sup> as increasingly main and important partners to infectious diseases physicians in implementation of antimicrobial stewardship programs<sup>41</sup>.

Hospital Pharmacist: Pharmacists major role because the effector arms for antimicrobial stewardship programs<sup>35</sup>. Due to their role in processing medication orders and their conversant in the hospital drug formulary. Pharmacists (IPD &OPD) may play major and different roles in antimicrobial stewardship programs. The First role is in processing medication orders and dispensing drugs within the hospital may note when restricted antimicrobials are ordered and notify the prescriber that authorization is required.

They may also flag orders for review by infectious diseases specialists, additionally to their usual role in assuring proper dosing and safety.

## **CLINICAL MICROBIOLOGIST**

Clinical Microbiologist is key of laboratory major component within the function of antimicrobial stewardship program. Clinical Microbiologist - guide accurate and reliable diagnostic assay for communicable disease. They can suggest empirical therapy derived from cumulative antibiotics resistant report available in hospital. Clinical microbiologist plays an important role in sending alert of multi drug resistant pathogens and

educate about the rapid diagnostic tests available in healthcare setting. Preparation of antibiograms specific to certain patient care areas, especially medical care units, may allow identification of local problems and focused antimicrobial stewardship and infection control effort<sup>42</sup>.

## **INFECTION CONTROL STAFF (INFECTION PREVENTION CONTROL COMMITTEE)**

Spread of antimicrobial-resistant organisms within hospitals has long been a priority of infection control professionals. Some resistant organisms have primarily been thought to play a serious role of spread of antimicrobial resistance<sup>43,44</sup>.

Dealing with MRSA: The proper method of control of methicillin-resistant *Staphylococcus aureus* in hospitals may be a contentious issue within the infection control community, with conflicting data on the effectiveness of stringent infection control measures<sup>45,46,47</sup>. A number of studies have suggested that the antimicrobial usage is significantly related to methicillin-resistant *S. aureus* rates, indicating that studies may have to regulate for antimicrobial use and infection control professionals should consider the effect of antimicrobial use in their institutions<sup>48</sup>.

## **HOSPITAL ADMINISTRATORS**

None of the efforts of infectious diseases physicians, pharmacists, microbiologists, or infection control practitioners to determine an antimicrobial stewardship program are likely to achieve success without hospital administration by hospital leadership<sup>49</sup>. Institutional policy, funding programming and physician autonomy are core issues within the development of antimicrobial stewardship programs that has got to be addressed by hospital administration.

Advocates of antimicrobial stewardship programs might had best to find out from the recent surge in patient safety initiatives at hospitals, spurred by the Institute of Medicine's 1999 report on adverse drug events<sup>50</sup>. Nowadays many institutions have large investments in new technology and personnel in an attempt to scale back medication errors<sup>51</sup>. Highlighting the adverse effects of antimicrobial resistance and nosocomial infections on patient outcomes may secure fresh commitments from hospital executives or a minimum of allow antimicrobial stewardship programs to piggyback onto newly funded patient safety initiatives<sup>52</sup>.

Hospital epidemiologists: Hospital epidemiologists have the expertise in surveillance and study design to lend to efforts studying the effect of antimicrobial stewardship measures. In turn, antimicrobial stewardship programs could also be ready to assist in efforts to regulate outbreaks by focused monitoring and/or restriction of antimicrobials within the targeted units.

## **DIAGNOSTIC STEWARDSHIP**

Diagnostic Stewardship may be an art, right diagnostic which are performed timely for right patient, before initiating antimicrobial therapy. Timely diagnostics which will appropriate and rapidly diagnose the patient's problems are vital (Diagnostic Stewardship Program). If all three aspects are covered – optimal treatment, prevention, and diagnostics (an integrated, Antimicrobial, Infection prevention & Diagnostic [AID] stewardship program) and everyone involved stakeholders have the required meta-competence, health-care centers can optimally treat infectious patients and face the event of antimicrobial resistance<sup>52, 53</sup>.

Many patient transfers between institutions also are pathogen transfers<sup>54</sup>, within a clearly defined region this is often the required close collaboration of all health-care facilities (i.e. hospitals, but also general practices and long-term care facilities)<sup>55</sup>. Regarding this aspect harmonization of guidelines and practices are required<sup>56</sup>.

### **Importance of diagnostics**

Proper diagnostics are performed on time and supply rapid results to make impact on patient care<sup>57</sup> when the starting of antimicrobial therapy resistance pattern should be available. Quality, cost, and time, these are the three parameters that influence the worth of diagnostic assay. Overall, the sensitivity and specificity of latest commercial and sometimes multiplex-based molecular, point-of-care (POC) assays approach the standard of laboratory developed tests.

**Table No. 3: Goal and key considerations for diagnostic stewardship**

Goals	Key questions	Key consideration and potential strategies
Right test	Is the test appropriate for the clinical setting?	<ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Predictive values</li> <li>• Volumes</li> <li>• Diagnostic yield</li> <li>• Laboratory feasibility</li> <li>• Cost</li> <li>• Clinical impact</li> </ul>
Right patient	Will the clinical care of the patient be affected by the test result?	<ul style="list-style-type: none"> <li>• Appropriate use criteria</li> <li>• Indication selection</li> <li>• Benchmarking Specimen rejection</li> </ul>
Right time	Will the result be available in time to optimally affect care?	<ul style="list-style-type: none"> <li>• Time to specimen receipt</li> <li>• Centralized vs point-of-care testing</li> <li>• On-demand vs batched testing</li> <li>• Specimen preparation time</li> <li>• Run time</li> <li>• Result reporting time</li> </ul>

**Table No. 4: Key antimicrobial stewardship for implementation of rapid diagnostic test**


GOAL	KEY QUESTION	KEY CONSIDERATIONS AND POTENTIAL STRATEGIES
Right interpretation	Will the clinician understand the test result?	<ul style="list-style-type: none"> <li>• Result report language</li> <li>• Selective reporting of relevant results</li> <li>• AS prospective audit and feedback</li> <li>• AS real-time decision support</li> </ul>
Right antimicrobial	Will the clinician Appropriately modify antimicrobials supported the test result?	<ul style="list-style-type: none"> <li>• Clinical practice guidelines</li> <li>• EMR based decision support with rest reporting</li> <li>• AS prospective audit and feedback</li> <li>• AS real-time decision support</li> </ul>
Right time	Will the clinician influence the test result promptly	<ul style="list-style-type: none"> <li>EMR report in Results called with read-back reporting</li> <li>AS prospective audit and feedback</li> <li>AS real-time decision support</li> </ul>

**Innovative Antimicrobial Stewardship PROGRAM (AMSP) Solutions Are Key**

The main aimed of AMSP to make sure the proper antibiotic is given to the proper patient for the proper amount of your time. The precise initiatives that hospitals prefer to implement are meant to integrate into the larger hospital workflow. There is no single prototype for a

program to reinforce antibiotic prescribing in hospital research identified. Flexibility in implementation is required thanks to the complexity of medical deciding surrounding antibiotic use and therefore the variation within the size of U.S. hospitals<sup>58, 59</sup>.

The CDC classifies antibiotic-stewardship initiatives into three categories: broad, pharmacy-driven, infection and syndrome-specific.



**Figure No. 2: Key components<sup>60, 61, 62</sup>**

Good antimicrobial steward

In 2001 Gerding write that we need to be exact antimicrobial stewards<sup>64</sup>. In Table we illustrate methods in which one-of-a-kind "actors" (individuals, organizations, governments) can do this, translating the definition of AMS into action. We recommend that the middle column can be used for when extraordinary actors prefer to carry what antimicrobial stewardship ability for them.

**Table No. 5: HOW WE CAN BE GOOD ANTIMICROBIAL STEWARD**

Actor	What it means to be good antimicrobial stewards	Example actions
PRESCRIBER	use antimicrobials responsibly by	<ul style="list-style-type: none"> <li>• Making correct diagnose</li> <li>• Following local antimicrobial guidelines</li> <li>• Regularly reviewing the want for therapy</li> </ul>
NURSE	I help ensure antimicrobials are used responsibly by	Taking cultures at excellent times <ul style="list-style-type: none"> <li>• Ensuring patients apprehend how to take antimicrobials on Discharge</li> </ul>
PATIENT	I use antimicrobials responsibly by	<ul style="list-style-type: none"> <li>• Taking antimicrobial courses as recommended by means of the prescriber</li> <li>• Not storing or using leftover antimicrobials</li> </ul>
AMSP TEAM	We assist others in our organization use antimicrobials responsibly by way of	Developing guidelines for antimicrobial use Supporting audit and feedback for prescribers
HOSPITAL GOVERNANCE	Our institution uses antimicrobials responsibly by	Ensuring adequate sustainable and committed funding for AMS teams <ul style="list-style-type: none"> <li>• Monitoring antimicrobial use and resistance</li> <li>• Investing in CDSS</li> <li>• Enabling formulary restrictions</li> </ul>
PRODUCER	I use antimicrobials responsibly by	<ul style="list-style-type: none"> <li>• Diagnosing selectivity</li> </ul>

Action within AMSP

- In this section, we will furnish examples of AMSP actions. Another evaluation in this sequence discusses the handy evidence base for interventions in clinic settings<sup>65</sup>. Figure 2 outline examples of movements by using specific people and organizations, focusing on human healthcare.

- To have an impact on the behavior of prescribers, patients, vets and farmers moves that

are taken, aiming to both enable better antimicrobial use or to prevent inappropriate or unnecessary antimicrobial use<sup>66</sup>. These actions may additionally be particularly termed “stewardship interventions” in the context of inpatient sanatorium care, and they are frequently coordinated by using a multidisciplinary group who lead an AMS Programme which selects from a menu of workable interventions that are adaptable and customizable concepts<sup>67</sup>,

Designed to fit the institutional infrastructure: how an antimicrobial stewardship team is embedded in the sanatorium infrastructure. Hospital best officers or advisors can support their work with understanding of nice implementation methodology (e.g. PDSA, six sigma, TOC) and involving implementation experts as stewardship groups. AMS program measures for first-rate improvement.

### **Structural indicators**

- Availability of multi-disciplinary antimicrobial stewardship team
- Provision of training in the closing 2 years Process measures
- Compliance with acute empiric guidance
- Percentage of fantastic de-escalation
- Percentage of splendid switch from IV to oral
- Compliance with surgical prophylaxis
- Compliance with care bundles Outcome measures
- C. difficile rates
- Surgical website online infection
- Surveillance of resistance
- Mortality Balancing measures
- Mortality
- SSI rates
- Re-admission within 30 days of discharge
- Admission to ICU
- Rate of complications
- Treatment-related toxicity Recent recommendations
- Antimicrobial stewardship must be monitored in ambulatory healthcare settings.

- Education about antimicrobial resistance and antimicrobial stewardship need to be accomplished.
- Antimicrobial use facts ought to be amassed and quite simply on hand for both inpatient and outpatient settings.
- Research on antimicrobial stewardship is wanted and must be funded by using the excellent federal agencies.

## CONCLUSION

Hospitalized sufferers grow to be extra complicated to treat, the increasing prevalence of antimicrobial resistance in both health care and neighborhood settings represents a daunting challenge. The increasing complexity of infections and a paucity of new antimicrobials in development, the future of successful antimicrobial remedy appears bleak. Antimicrobial stewardship can grant all practitioners with tools to stop the overuse of precious assets and assist control the make bigger in antimicrobial resistance. Although often underappreciated, the make bigger of antimicrobial resistance has eventually caught the interest of influential worldwide health care organizations.

Antimicrobial stewardship is central to efforts to ensure get right of entry to nice antimicrobials for all who need them, these days and tomorrow. The time period AMSP emerged quite recently, and is being applied in an increasing more various vary of contexts; many modern definitions of AMS are technical and focal point on prescriptions. We have counseled that it is best to view AMS extra broadly, as a strategy, a coherent set of actions designed to use antimicrobials responsibly. The precise moves fluctuate depending on the actor, however, share many commonalities at different ranges inside a healthcare system, as properly as between human and animal health.

Our advised definition for AMS is a tool: every actor can ask if they or their corporations are undertaking moves to use antimicrobials responsibly, and if these actions are coherent. Going forward, there is a non-stop want for “responsibly” to be described and translated into context- and time-specific act.

## REFERENCES

1. Anonymous.1999. Tengreat public health achievements–United States,1900 1999. *Morb. Mortal. Wkly.*



- Rep.48:241–243.
2. Anonymous.1999. Tengreat public health achievements–United States,1900 1999.Morb.Mortal.Wkly. Rep.48:241–243.
  3. Armstron G.L.,L.A. Conn, and R.W.Pinner.1999. Trends in infectious disease mortality in the United States during the 20<sup>th</sup> century.JAMA281:61–66.
  4. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009; 15(Suppl 3):12–15.DOI.10.1111/j.1469-0691.2009.02725.x
  5. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24:718–733. DOI: 10.1128/CMR.00002-11.
  6. Renwick MJ, Simpkin V, Mossialos E. International and European initiatives targeting innovation in antibiotic drug discovery and development. The need of a one health – one Europe – one world framework. Den Haag, Netherlands: Dutch Ministry of Health; 2016. p. 1–93.PMID:28806044
  7. World Health Organization. The evolving threat of antimicrobial resistance – options for action. Geneva, Switzerland; 2012; [cited 2016 Feb 22]. Available from: [http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181_eng.pdf)doi.org/10.1016/j.jiph.2016.03.003
  8. Dellit T, Owens R, McGowan J, et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–177.DOI:10.1086/510393,PMID:17173212
  9. With de K, Allerberger F, Amann S, et al. S3-Leitlinie. S3-Guideline: strategies to enhance rational use of antibiotics in hospital. Infection. 2016. doi:10.1007/s15010-016-0885-z. [Epub ahead of print]
  10. SWAB. De kwaliteit van het antibioticabeleid in Nederland; 2012; [cited 2016 Feb 22]. Availablefrom:[http://www.swab.nl/swab/cms3.nsf/uploads/5FD2BE2700E8B433C1257A680028D9F0/\\$FILE/v isiedoc%20SWAB%20vs%2021%20junifinal.pdf](http://www.swab.nl/swab/cms3.nsf/uploads/5FD2BE2700E8B433C1257A680028D9F0/$FILE/v%20isiedoc%20SWAB%20vs%2021%20junifinal.pdf).DOI:10.1080/14787210.2016.1178064
  11. Davey P, Brown E, Charani E, et al. Interventions to improve anti- biotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013; 4:CD003543. ,DOI:10.1002/14651858.CD003543.pub4,PMID:28178770
  12. Schuts EC, Hulscher MEJL, Mouton JW, et al. A systematic review and meta-analysis of current evidence on hospital Antimicrobial Stewardship objectives. Lancet Infect Dis. 2016. pii:S1473-3099(16) 00065-7. doi:10.1016/S1473-3099(16)00065-7. [Epub ahead of print] Highly extensive systematic review and meta-analysis, giving a complete overview on the effects of ASPs. Penicillin’s finder assays its future: Sir Alexander Fleming says improved dosage method is needed to extend use other scientists praised self-medication decried. The New York Times. June26,1945.
  13. Shlaes DM, Gerding DM, John JF, et al. Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275-291.
  14. CDC. Antibiotic prescribing and use in hospitals and long-term care. [www.cdc.gov/antibiotic-use/healthcare/](http://www.cdc.gov/antibiotic-use/healthcare/). Accessed February 24,2014.
  15. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews.2013;4. DOI:10.1002/14651858.CD003543.pub4,PMID;28178770,
  16. Joint Commis, Mc Gowan JE, Gerding DN. Does antibiotic restriction prevent resistance? New Horiz 1996;4:370–6.PMID:8856755
  17. Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, et al. Society for Health care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–91,DOI:10.1086/513766,PMID:9314444
  18. Gould IM. Stewardship of antibiotic use and resistance surveillance: the international scene. J Hosp Infect 1999;43 Suppl:S253-60,,DOI:10.106/s0195-6701(99)90095-6,PMID:10658788
  19. Kazanjian P. Chapter 3: History of Antimicrobial Stewardship. In: LaPlante K, editor. Antimicrob. Steward. Princ. Pract., CABI; 2016
  20. Stewardship Definition by Merriam- Webster n.d. <https://www.merriam-webster.com/dictionary/stewardship> (accessed April 17, 2017).
  21. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious

Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007;44:159–77. DOI:10.1086/510393.

22. Fishman N. Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). *Infect Control HospEpidemiol* 2012;33:322–7. DOI:10.1086/665010.

23. NNIS System; Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. *Am J Infect Control*. 2003;31(8):481-498.

24. Kallen AJ, Mu Y, Bulens S, et al. Healthcare-associated invasive MRSA infections, 2005–2008. *JAMA*. 2010;304(6):641-648.

25. Hageman JC, Patel JB, Carey RC, Tenover FC, McDonald LC. Investigation and control of vancomycin-intermediate and -resistant *Staphylococcus aureus* (VISA/VRSA): a guide for health departments and infection control personnel. [http://www.cdc.gov/ncidod/dhqp/pdf/ar/visa\\_vrsa\\_guide.pdf](http://www.cdc.gov/ncidod/dhqp/pdf/ar/visa_vrsa_guide.pdf). 2006. Accessed September 7, 2011.

26. Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. *Infect Control HospEpidemiol*. 2010; 31(suppl1):S51-S54. DOI:10.1080/21505594.2016.1159366, PMID:26984779,

27. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). *J Antimicrob Chemother*. 2006; 58(1):205-210. DOI: 10.1093/jac/dki117

28. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. *Chest*. 2001; 119(2)(suppl):397S-404S. PMID:11292878, DOI:10.1097/00003246-200104001-00002

29. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis*. 2007; 44(2):159-177. DOI:10.1086/510393, PMID: 17173212 ,

30. Rifenburg, R. P., J. A. Paladino, S. C. Hanson, J. A. Tuttle, and J. J. Schentag. 1996. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. *Am. J. Health Syst. Pharm.* 53:2054–2062, DOI:10.1086/510393, PMID:17173212

31. Rifenburg, R. P., J. A. Paladino, S. C. Hanson, J. A. Tuttle, and J. J. Schentag. 1996. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. *Am. J. Health Syst. Pharm.* 53:2054–2062, DOI: 10.1186/cc1022, PMID: 1151133

32. CDC. Antibiotic prescribing and use in hospitals and long-term care. Core elements of hospital antibiotic stewardship programs. February 23, 2017. [www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html#\\_ENREF\\_57](http://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html#_ENREF_57). Accessed January 21, 2018

33. Bhavnani, S.M. 2000. Benchmarking in health-system pharmacy: current research and practical applications. *Am. J. Health Syst. Pharm.* 57(Suppl.2):S13–20. doi.org/10.1590/S1413-86702003000500002

34. Struelens, M. J. 2003. Multidisciplinary antimicrobial management teams

35. Knox, K., W. Lawson, B. Dean, and A. Holmes. 2003. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist—a UK perspective. *J. Hosp. Infect.* 53:85–90., DOI:10.1016/s0195-6701(03)00155-5, PMID:12855244

36. Carmichael, J. M., M. B. O’Connell, B. Devine, H. W. Kelly, L. Ereshefsky, W. D. Linn, and G. L. Stimmel. 1997. Collaborative drug therapy management by pharmacists. *American College of Clinical Pharmacy. Pharmacotherapy* 17:1050–1061, DOI: 10.1128/CMR.18.4.638-656.2005, PMID: 16223951

37. Gattis, W. A., V. Hasselblad, D.J. Whellan, and C.M. O’Connor. 1999. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. *Arch. Intern. Med.* 159:1939–1945., DOI:10.1001/archinte.159.16.1939, PMID:10493325

38. Leape, L.L., D.J. Cullen, M.D. Clapp, E. Burdick, H.J. Demonaco, J.I. Erickson, and D.W. Bates. 1999.

- Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. *JAMA*282:267–270
39. Gross, R., A.S. Morgan, D.E. Kinky, M. Weiner, G.A. Gibson, and N.O. Fishman. 2001. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. *Clin. Infect. Dis.* 33:289–295.,DOI:10.1001/jama.282.3.267,PMID:10422996
40. Weller, T. M., and C. E. Jamieson. 2004. The expanding role of the antibiotic pharmacist. *J. Antimicrob. Chemother.* 54:295–298 DOI:10.1093/jac/dkh327,PMID:15201228,
41. Stratton, C.W.,H. Ratner, P.E. Johnston, and W. Schaffner.1993.Focused microbiologic surveillance by specific hospital unit: practical application and clinical utility. *Clin. Ther.* 15(Suppl. A):12–20
42. Rice, L. B. 2003. Controlling antibiotic resistance in the ICU: different bacteria, different strategies. *Cleve. Clin. J. Med.* 70:793–800,DOI:10.3949/ccjm.70.9.793,PMID:14518574
43. Safdar, N., and D.G. Maki.2002. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant *Staphylococcus aureus*, *enterococcus*, *gram-negative bacilli*,DOI:10.7326/0003-4819-136-11-200206040-00013,PMID:12044132,
44. Boyce, J.M., N.L. Havill, C.Kohan, D.G. Dumigan, and C.E. Ligi. 2004. Do infection control measures work for methicillin-resistant *Staphylococcus aureus*? *Infect. Control Hosp. Epidemiol.*25:395–401DOI: <https://doi.org/10.1086/502412>
45. Cooper, B.S., S.P. Stone, C.C. Kibbler, B.D. Cookson, J.A. Roberts, G.F. Medley, G. Duckworth, R. Lai, and S. Ebrahim. 2004. Isolation measures in the hospital management of methicillin resistant *Staphylococcus aureus* (MRSA): systematic review of the literature. *Br. Med. J.*329:533.DOI:10.1136/bmj.329.7465.533
46. Craig, W.A., S.J. Uman, W.R. Shaw, V. Ramgopal, L.L. Eagan, and E.T. Leopold. 1978. Hospital use of antimicrobial drugs. Survey at 19 hospitals and results of antimicrobial control program. *Ann. Intern. Med.*89:793–799 ,DOI: 10.1111/j.1365-2125.1984.tb02493.x,PMID: 6386026
47. Monnet, D. L. 1998. Methicillin-resistant *Staphylococcus aureus* and its relationship to antimicrobial use: possible implications for control. *Infect. Control Hosp. Epidemiol.* 19:552–559.,DOI:10.1086/647872,PMID:9758054
48. Goldmann, D. A., R. A. Weinstein, R. P. Wenzel, O. C. Tablan, R. J. Duma, R.P. Gaynes, J. Schlosser, and W.J. Martone. 1996. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. *JAMA*275:234–240PMID:8604178
49. Institute of Medicine. 1999. To err is human: building a safer health system. National Academy Press, Washington, D.C.
50. Wachter, R. M. 2004. The end of the beginning: patient safety five years after ‘To Err Is Human’. *Health Affairs* W4:534–545.
51. Gerberding, J. L. 2002. Hospital-onset infections: a patient safety issue. *Ann. Intern. Med.* 137:665–670.
52. Lammie SL, Hughes JM. Antimicrobial resistance, food safety, and one health: the need for convergence. *Ann Rev Food Sci Technol.* 2016; 7:287–312,DOI:10.1146/annurev-food-041715-033251,PMID:26772408
53. Dik JH, Poelman R, Friedrich AW, et al. An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID). *Future Microbiol.* 2016; 11:93–102.DOI: 10.2217/fmb.15.99
54. Donker T, Wallinga J, Grundmann H. Patient referral patterns and the spread of hospital-acquired infections through national health care networks. *PLoS Comput Biol.* 2010; 6(3):e1000715.DOI.org/10.1371/journal.pcbi.1000715
55. Ciccolini M, Donker T, Köck RR, et al. Infection prevention in a connected world: the case for a regional approach. *Int J Med Microbiol.* 2013; 303:380–387DOI:10.1016/j.ijmm.2013.02.003,PMID:23499307,
56. Müller J, Voss A, Köck R, et al. Cross-border comparison of the Dutch and German guidelines on multidrug-resistant gram-negative microorganisms. *Antimicrob Resist Infect Control.* 2015; 4:7. DOI: 10.1080/14787210.2016.1178064
57. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: improved diagnostics for infectious diseases. *Clin*
58. American Society of Health-System Pharmacists. Implementing antimicrobial stewardship programs in health systems: an inter professional team approach. 2013 [www.ashpadvantagemedia.com/downloads/2013-asp-discussion-guide.pdf](http://www.ashpadvantagemedia.com/downloads/2013-asp-discussion-guide.pdf). Accessed March 8, 2018
59. Yam P, Fales D, Jemison J, et al. Implementation of an antimicrobial stewardship program in a rural

- hospital. Am Journal Health Syst Pharm. 2012;69(13):1142-1148. Infect Dis. 2013;57(Suppl3):S139S170, DOI: <https://doi.org/10.1186/2052-3211-7-10>
60. Kapadia SN, Abramson EL, Carter EJ, et al. The expanding role of antimicrobial stewardship programs in hospitals in the United States: lessons learned from a multi site qualitative study. *Jt Comm J Qual Patient Saf*, 2018; 44 (2):68-74. DOI:10.1016/j.jcjq.2017.07.007, PMID:29389462,
61. CDC. Antibiotic prescribing and use in hospitals and long-term care. Core elements of hospital antibiotic stewardship programs. February 23, 2017. [www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html#\\_ENREF\\_57](http://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html#_ENREF_57). Accessed January 21, 2018.
62. Kullar R, Golf DA, Schultz LT, et al. The “epic” challenge of optimizing antimicrobial stewardship: the role of electronic medical records and technology. *Clin. Infect. Dis.* 2013; 57: 1005-120. Kuper K. What makes a successful antibiotic stewardship. DOI: 10.3390/pharmacy4040032
63. Kuper K. What makes a successful antibiotic stewardship program? *Drug Topics*. November 10, 2017. [drugtopics.modernmedicine.com/drug-topics/news/what-makes-a-successful-antibiotic-stewardship-program](http://drugtopics.modernmedicine.com/drug-topics/news/what-makes-a-successful-antibiotic-stewardship-program). Accessed March 8, 2018., DOI: 10.3949/ccjm.84gr.17003, PMID: 28885907
64. Gerding DN. These arch for good antimicrobial stewardship. *Jt Comm J Qual Improv* 2001; 27: 403–4.
65. Hulscher M, Prins J. Antibiotic stewardship: does it work in hospital practice? An evidence based review. *Clin Microbiol Infect* 2017.
66. Davey P, Marwick CA, Scott CL, Charani E, Mc Neil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. In: Davey P, editor. *Cochrane Database Syst. Rev.*, Chichester, UK: John Wiley & Sons, Ltd; 2017. doi:10.1002/14651858.CD003543.pub4.
67. Septimus EJ, Owens RC. Need and potential of antimicrobial stewardship in community hospitals. *Clin Infect Dis* 2011; 53Suppl1:S8–14. doi:10.1093/cid/cir363



	<p><b>1- Vipin Kumar – Main Author</b></p> <p>Clinical Pharmacologist</p> <p>Narayana Superspeciality Hospital Gurugram (Haryana)</p>
	<p><b>2- Dr .Malvika Srivastava - Corresponding Author</b></p> <p>Microbiologist &amp; Infection Control Officer</p> <p>Narayana Superspeciality Hospital Gurugram (Haryana)</p>
	<p><b>3-Dr Sachin Gupta</b></p> <p>(Critical Care H.O.D)</p> <p>Narayana Superspeciality Hospital Gurugram (Haryana)</p>
	<p><b>4-Dr Swadesh</b></p> <p>(Deputy Medical Superintendent &amp; Emergency Head)</p> <p>Narayana Superspeciality Hospital Gurugram (Harya)</p>
	<p><b>5-Dr Satish Kaul</b></p> <p>(Internal Medicine H.O.D)</p> <p>Narayana Superspeciality Hospital Gurugram (Haryana)</p>
	<p><b>6-Dr Vipin Kumar Sharma</b></p> <p>(Assistant Professor)</p> <p>Gurukul Kangri University Haridwar</p>
	<p><b>7-Ankita Singh</b></p> <p>Clinical Pharmacist</p> <p>Blk Hospital New Delhi</p>